Key Considerations for the Lenvatinib-Pembrolizumab-Chemotherapy Regimen in Advanced Gastric Cancer: Insights From LEAP-015

Zhengqi Jiang

Zhengqi Jiang, MD, and Yandong Xiang, MD, Department of Gastrointestinal Surgery, Xiangya Third Hospital, Central South University, Changsha, Hunan, China; and Bo Yi, MD, PhD, Department of Gastrointestinal Surgery, Chongqing University Cancer Hospital, Chongqing, China

Yandong Xiang

Zhengqi Jiang, MD, and Yandong Xiang, MD, Department of Gastrointestinal Surgery, Xiangya Third Hospital, Central South University, Changsha, Hunan, China; and Bo Yi, MD, PhD, Department of Gastrointestinal Surgery, Chongqing University Cancer Hospital, Chongqing, China

Bo Yi

Department of Chemistry and Biotechnology Graduate School of Engineering The University of Tokyo 7‐3‐1 Hongo, Bunkyo‐ku Tokyo 113‐8656 Japan